Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]

Recenti progressi in medicina - 1 Jun 2018

Fasola Gianpiero, De Carlo Elisa, Grossi Francesco

Abstract excerpt

The checkpoint inhibitors opened a new era in the treatment of advanced non-small-cell lung cancer (NSCLC) initially by replacing second-line standard chemotherapy with docetaxel and subsequently by replacing platinum-based chemotherapy in the first line, albeit in patients selected for a high expression of PD-L1. The decision algorithm has therefore been radically modified for patients who do not have activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Decision Making

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 29968861
DOI: 10.1701/2932.29487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]PMID 29968861Read ↗

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read ↗

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.Semantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

[Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines].Semantic proximity Read ↗

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.Semantic proximity Read ↗

[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?Semantic proximity Read ↗

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.Semantic proximity Read ↗

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.Semantic proximity Read ↗

Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort StudySemantic proximity Read ↗

The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-AnalysisSemantic proximity Read ↗

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.